水飞蓟宾联合壳脂胶囊治疗非酒精性脂肪肝病患者的前瞻性研究  

Prospective study on nonalcoholic fatty liver disease treated with silibinin combined with Kezhi capsules

作　　者：刘晓宇 姜红[1] 刘玲玲 Liu Xiaoyu;Jiang Hong(Department of Gastroenterology,Laiyang Central Hospital of Yantai,Yantai 265200,China)

机构地区：[1]烟台市莱阳中心医院消化内科,265200 [2]不详

出　　处：《国际医药卫生导报》2018年第7期1068-1072,共5页International Medicine and Health Guidance News

摘　　要：研究壳脂胶囊与水飞蓟宾联合治疗非酒精性脂肪肝病患者的疗效。方法 选取本院2015年1月至2017年6月非酒精性脂肪肝病患者137例，依据治疗方式不同分组，对照组68例予以水飞蓟宾治疗，研究组69例于对照组基础上联合壳脂胶囊治疗，统计两组患者疗效及不良反应发生率，比较两组血清肝功能指标[丙氨酸氨基转移酶（ALT）、总胆红素（TBIL）、白蛋白（ALB）、天冬氨酸氨基转移酶（AST）水平]及血脂指标[总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白（LDL-C）水平]，对比两组患者治疗前及治疗3个月后生活质量（WHOQOL-100）评分。结果 研究组疗效优于对照组，且研究组总有效率高于对照组[98.55%（68/69）比83.82%（57/68）]，差异有统计学意义（P＜0.05）；研究组治疗3个月后血清ALT、TBIL、ALB、AST水平较对照组低，差异均有统计学意义（均P＜0.05）；研究组治疗3个月后血清TC、TG、LDL-C水平较对照组低，差异有统计学意义（均P＜0.05）；研究组不良反应总发生率与对照组比较差异无统计学意义[5.80%（4/69）比2.94%（2/68），P＞0.05]；研究组治疗3个月后WHOQOL-100评分高于对照组（[89.61±8.24）比（80.52±7.86）]，差异有统计学意义（t=6.605，P=0.000）。结论 非酒精性脂肪肝病患者予以壳脂胶囊与水飞蓟宾联合治疗效果显著，可有效改善其肝功能及血脂水平，提升其生活质量，且具有安全性。To investigate the curative effect of silibinin combined with Kezhi capsules in the treatment of patients with nonalcoholic fatty liver disease.Methods A total of 137 patients with nonalcoholic fatty liver disease in our hospital from January 2015 to June 2017 were divided into two groups according to different treatment methods.68 cases in the control group were treated with silibinin,and 69 cases in the study group were treated with Kezhi capsules on the basis of the control group.The effect and the incidence of adverse reactions of the two groups were statistically recorded.The levels of serum liver function indexes[alanine aminotransferase(ALT),total bilirubin(TBIL),albumin(ALB),aspartate aminotransferase(AST)]and blood lipid indexes[total cholesterol(TC),triglyceride(TG),and low density lipoprotein(LDL-C)]of the two groups were measured.The quality of life(WHOQOL-100)scores were compared between the 2 groups before and after 3 months of treatment.Results The effect of the study group was better than that of the control group,and the total effective rate of the study group was 98.55%(68/69),higher than that of the control group[83.82%(57/68)](P<0.05).The levels of serum ALT,TBIL,ALB,and AST in the study group were lower than those in the control group after 3 months of treatment(P<0.05).The levels of serum TC,TG,and LDL-C in the study group were lower than those in the control group after 3 months of treatment(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions between the study group[5.80%(4/69)]and the control group[2.94%(2/68)](P>0.05).After 3 months of treatment,the score of WHOQOL-100 in the study group[(89.61±8.24)points]was higher than that in the control group[(80.52±7.86)points](t=6.605,P=0.000).Conclusion The combination of silibinin and Kezhi capsules is effective in the treatment of nonalcoholic fatty liver disease,which can effectively improve the liver function and blood lipid level,and improve the quality of life,with high safety.

关 键 词：壳脂胶囊 水飞蓟宾 非酒精性脂肪肝病 丙氨酸氨基转移酶 总胆红素 

分 类 号：R575.5[医药卫生—消化系统]